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Background: The protease-activated receptor 1 (PAR1), encoded by F2R, is found on the surfaces of platelets and vascular endothelial cells. 
Thrombin potently activates PAR1 (and PAR4) on human platelets. Phase III studies of PAR-1 antagonists administered to patients managed with 
dual anti-platelet therapy have failed to show a benefit in prevention of subsequent coronary events. The intronic single nucleotide polymorphism 
(SNP), F2R IVS-14A/T (rs168753) has been shown to be associated with platelet receptor density and functional response of PAR-1. The aim of this 
study was to evaluate the effect of rs168753 on the occurrence of subsequent stent thrombosis and cardiovascular outcome.
Methods: Using BioVU, the Vanderbilt DNA repository linked to the electronic health record (EHR), we identified individuals who had an MI or 
underwent PCI with stent placement, using a combination of billing codes, laboratory values, medication orders, and natural language processing 
derived from EMR data. Cases had a recurrent cardiovascular event, defined as a composite outcome of MI, revascularization, stroke, or all-cause 
mortality (n=224). Controls were observed for at least one year without a second cardiovascular event (n=468).
Results: The native A/A genotype was found among 456 patients (56%); while 150 patients (18%) contained one allele with the A to T transversion 
(A/T) and 19 (2.3%) were homozygous (TT). Using an additive Cox regression model, There was no significant difference for the primary outcome 
between cases and controls (HR 1.20, 95% CI 0.90-1.60, p = 0.21). This relationship persisted (HR 1.19, 95% CI 0.89-1.59, p=0.23) when our 
model was adjusted for age, race, gender, bmi and smoking status. In addition, SNP rs168753 was not associated with the secondary endpoint of 
stent thrombosis (n=11) (HR 2.25, 95% CI 0.31-16.62, p=0.43).
Conclusions: In this population, our data do not support an association between rs168753 and recurrent cardiac events, including stent 
thrombosis.
